Chemotherapy for adult soft tissue sarcoma. Does it work?

Acta Orthopaedica Scandinavica, Supplement

Volumn 68, Issue 273, 1997, Pages 139-144

  Saeter G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IFOSFAMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; HUMAN; MULTIDRUG RESISTANCE; PROGNOSIS; REVIEW; SOFT TISSUE SARCOMA; TUMOR LOCALIZATION; ADULT; CLINICAL TRIAL; DOSE RESPONSE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; SARCOMA; SOFT TISSUE TUMOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; HUMANS; PROGNOSIS; RESEARCH DESIGN; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0031066347     PISSN: 03008827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Enzinger FM, Weiss SW. General considerations; in Enzinger FM, Weiss SW (eds): Soft tissue tumors. St. Louis, Mosby, 1988, pp 1-18.
2. Torosian MH, Friedrich C, Godbold J, et al. Soft-tissue sarcoma: initial characteristics and prognostic factors in patients with and without metastatic disease. Semin Surg Oncol 1988; 4:13-9.
3. Antman KH, Elias AD. Chemotherapy of advanced soft-tissue sarcomas. Semin Surg Oncol 1988; 4: 53-8.
4. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma: Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506-11.
5. Dombemowsky P, Buesa J, Pinedo HM, et al. VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol 1987; 23: 579-80.
6. Welt S, Magill GB, Sordillo PP, et al. Phase II trial of VP-16-213 in adults with advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 1983; 3: 234.
7. Saner G, Talle K, Solheim Ø. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continous-infusion etoposide. Cancer Chemother Pharmacol 1995; 36: 172-5.
8. Schmidt RA, Conrad EU, III, Collins C, et al. Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 1993; 72: 2593-601.
9. Valeriote FA, Edelstein M. Cellular basis for infusional chemotherapy; in Lokich JJ (ed): Cancer chemotherapy by infusion. 1990, pp 42-52.
10. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors in advanced soft tissue sarcoma (STS): an overview of 1742 patients treated with doxorubicin containing first line regimens by the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol 1994; 5 Suppl. 8: 171
11. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840-50.
12. Baker LH, Frank J, Fine G, et al. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group study (7613). J Clin Oncol 1987; 5: 851-61.
13. Yap BS, Baker LH, Sinkovics JG, et al. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 1980; 64: 93-8.
14. Bramvvell VHC. Chemotherapy for metastatic soft tissue sarcoma - another full circle? Br J Cancer 1991; 64: 7-9.
15. Schutte J, Mouridsen HT, Steward W, et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 1993; 31 Suppl 2: S204-9.
16. Antman K, Crowley J, Balcerzak SP, et al. An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-85.
17. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7: 1208-16.
18. Saeter G, Strander H, Monge OR, Alvegård TA. Dose escalating etoposide (E), ifosfamide (I) and granulocyte-colony stimulating factor (G-CSF) (VIG regimen) in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group study. Ann Oncol 1994; 5 Suppl. 8: 171.
19. SaMer G. Treatment of bone and soft tissue sarcomas. The role of chemotherapy, dose-response relationships and haematopoietic growth factors. Denis L (ed): Gardiner-Caldwell Communications Ltd. 1996,
20. van Haelst Pisani CM, Buckner JC, Reiman HM, et al. Does histologie grade in soft tissue sarcoma influence response rate to systemic chemotherapy? Cancer 1991; 68: 2354-8.
21. Pinedo HM, Bramwell VHC, Mouridsen HT, et al. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC soft tissue and bone sarcoma group. Cancer 1984; 53: 1825-32.
22. Benjamin RS, Legha SS, Patel SR, Nicaise C. Singleagent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 1993; 31 Suppl 2: S174-9.
23. Cemy T, Leyvraz S, Brunner G, et al. High-dose ifosfamide with mesna and GM-CSF in refractory sarcoma patients: clinical data and pharmacokinetics. Ann Oncol 1992; 3: 114
24. Patel SR, Hays C, Papadopoulos NE, et al. Pilot study of high-dose ifosfamide (HDI) + G-CSF in patients (pts) with bone and soft-tissue sarcomas. Proc Am Soc Clin Oncol 1995; 14: 516
25. Brain E, Le Cesne A, Le Chevalier T, et al. High-dose ifosfamide (HDI) can circumvent resistance to standard-dose ifosfamide (SDI) in advanced soft tissue sarcomas (ASTS). Proc Am Soc Clin Oncol 1993; 12: 1641
26. Stein U, Shoemaker RH, Schlag PM. MDRl gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer 1996; 32A: 86-92.
27. Pinedo HM, Giaccone G. P-glycoprotein - a marker of cancer cell behavior. N Engl J Med 1995; 333: 1417-9.
28. Mertens WC, Bramwell VH. Adjuvant chemotherapy in the treatment of soft-tissue sarcoma. Clin Orthop 1993; 81-93.
29. Antman K, Ryan L, Borden E, et al. Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results and review of the literature; in Salmon SE (ed): Adjuvant therapy of cancer VI. Philadelphia, W.B. Saunders, 1990, pp 529-543.
30. Tierney JF, Mosseri V, Stewart LA, et al. Adjuvant chemotherapy for soft-tissue sarcoma: Review and metaanalysis of the published results of randomised clinical trials. Br J Cancer 1995; 72: 469-75.
31. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand 1994; 65, Supp 1259: 1-31.
32. Pfeffer MR, Sulkes A, Biran S. Cyclophosphamide, adriamycin, dtic and vincristine with methotrexate in the treatment of advanced soft tissue sarcomas. Isr J Med Sci 1988; 24: 599-603.
33. Wiklund T, Sæer G, Strander H, et al. Outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience. Eur J Cancer 1996; in press.
34. Lanza LA, Putnam JBJ, Benjamin RS, Roth JA. Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. Ann Thorac Surg 1991: 51: 219-24.
35. Sæer G, Alvegård TA, Monge O, et al. VIG chemotherapy in advanced soft tissue sarcoma - results of the Scandinavian Sarcoma Group SSG X trial. Acta Orthop Scand 1995; 66 Suppl 265: 93-4.